Patient info Open main menu

Nacl 0.45% w/v, KCL 0.15% w/v & Glucose 5% w/v IV infusion – patient leaflet, side effects, dosage

Text from the MHRA, as of · About this document

Medicine strength:
0.45% w/v
Contains active substances:

Patient leaflet - Nacl 0.45% w/v, KCL 0.15% w/v & Glucose 5% w/v IV infusion

1. WHAT NACL/KCL/GLUCOSE INFUSION IS AND WHAT IT IS USED FOR

NaCI/KCl/glucose infusion is a sterile solution that does not produce fever. NaCI/KCl/glucose infusion is used to maintain electrolyte (salt) balance after an operation. (You will need blood tests to make sure you do not receive too much potassium. This is a risk in patients with kidney failure.)

2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN NACL/KCL/GLUCOSE

You may not be given NaCI/KCl/glucose infusion if you have any of the following conditions:

  • Addison's disease (a disease which causes salt to be lost in the urine)

    • Adrenal insufficiency (a problem affecting the adrenal gland)
    • Kidney disease
    • Little or no urine produced
    • High potassium levels (can be detected by a test carried out by a doctor).

You may also not be able to receive dextrose (a sugar) infusion if you have a liver disorder.

Warnings and precautions

Before you are given NaCI/KCl/glucose infusion, a solution containing no potassium may be given first to make sure your kidneys are working properly.

Other medicine and NaCl/KCl/glucose

Tell your doctor if you are

  • receiving potassium-containing solutions.
  • taking a potassium-sparing diuretic (water tablets such as amiloride)

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Pregnancy and breast-feeding

Please tell your doctor if you are pregnant, think you are pregnant or breast-feeding.

Important information about some of the ingredients of NaCI/KCl/glucose infusion

NaCI/KCl/glucose infusion contains sodium and potassium. This will be taken into consideration for patients on a controlled sodium or potassium diet or for patients with a kidney disorder.

NaCI/KCl/glucose infusion also contains glucose. If you have been told by your doctor that you have an intolerance to some sugars, tell your doctor.

3. HOW YOU ARE GIVEN NACL/KCL/ GLUCOSE INFUSION

NaCI/KCl/glucose infusion will be given to you as an infusion (into a vein) in hospital by a doctor or a nurse.

Adults:

The dose used will depend upon the patient's condition. The rate of infusion should be no more than 10-20 mmols of potassium per hour. The maximum daily dose of potassium is 200 mmols.

Children:

Children may need a reduced dose.

Elderly:

The elderly may need a reduced dose particularly if they have a heart or kidney disorder.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

If you are given more NaCI/KCl/glucose infusion than you should

It is very unlikely, as your doctor will know the correct amount to use.

You may experience symptoms relating to low blood pressure and a disturbed heart rhythm. However, tell your doctor if you have any concerns. If you have any further questions on the use of this medicine, ask your doctor.

4. POSSIBLE SIDE EFFECTS

Like all medicines, NaCI/KCl/glucose can cause side effects, although not everybody gets them.

The following side effects have been reported:

  • lack of energy or interest,
  • confusion,
  • pins and needles,
  • weakness,
  • low blood pressure,
  • disturbed heart rhythm, and sometimes heart attack.

A blood clot in the infused vein has also been reported.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at:

www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

5. HOW TO STORE NACL/KCL/GLUCOSE INFUSION

Keep this medicine out of the sight and reach of children.

Your doctor and hospital pharmacist are responsible for the correct storage, use and disposal of NaCI/KCl/glucose infusion. NaCI/KCl/glucose infusion should be stored below 25°C.

Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month. Any unused solution should be discarded.

6. CONTENTS OF THE PACK AND OTHER INFORMATION

What NaCI/KCl/glucose infusion contains:

Sodium Chloride BP 0.45% w/v Potassium Chloride BP 0.15% w/v Glucose anhydrous BP 5.00% w/v Water for Injections BP

What NaCI/KCl/glucose infusion looks like and contents of the pack.

NaCI/KCl/glucose infusion comes in PVC containers in the following sizes:

500 ml, 1000 ml

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer:

Terumo BCT Ltd.

Old Belfast Road

Millbrook

Larne

Northern Ireland

BT40 2SH

United Kingdom

For any information about this medicinal product, please contact Marketing Authorisation Holder:

This leaflet was last approved in June 2016

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 21538/0014

MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Nacl 0.45% w/v, KCL 0.15% w/v & Glucose 5% w/v IV infusion

Active substances Potassium chloride, Sodium chloride
Strength 0.45% w/v
Excipients Water for Injections BP
Shelf life 2 years from the date of manufacture.
Storage Store below 25°C.
Drug group (ATC) Electrolytes with Carbohydrates
  1. B Blood and blood forming organ drugs
    1. B05 Blood substitutes and perfusion solutions
      1. B05B IV solutions used in parenteral administration of fluids, electrolytes and nutrients
        1. B05BB Solutions affecting the electrolyte balance
          1. B05BB02 electrolytes with carbohydrates
Marketing authorisation PL 21538/0014 (first authorised 18 March 2009)
Marketing authorisation holder Terumo BCT Ltd.

Sources: the MHRA product information (products.mhra.gov.uk). Contains public sector information licensed under the Open Government Licence v3.0.